The Rationale for not Routinely Purging Autologous Blood Stem Cell Grafts

References

• Demirer, T., Gooley, T., Buckner, C. D., Petersen, F. B., Lilleby, K., Rowley, S., Sanders, J., Storb, R., Appelbaum, FR. and Bensinger, WI. (1995). Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. Bone Marrow Transplant, 15, 907–913.
   PubMed Web of Science ®Google Scholar
• Gorin, N. C. (1992). High-dose therapy for acute myelocytic leukemia. In: High-dose cancer therapy (pharmacology, hematopoietins, stem cells) Armitage, J. O. and Antman, K. H. (Eds.), pp. 569–606. Baltimore, MD., Williams and Wilkins.
   Google Scholar
• Hill, R. S., Mazza, P., Amos, D., Buckner, C. D., Appelbaum, F. R., Still, B. J., Berenson, R., Bensinger, W., Clift, R. A., Stewart, P., Doney, K., Sanders, J., Singer, J., Sullivan, K. M., Witherspoon, R. P., Storb, R., Livingston, R., Chard, R. and Thomas, E. D. (1989). Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation. Bone Marrow Transplant, 4, 69–74.
   PubMed Web of Science ®Google Scholar
• Negrin, R. S., Kusnierz-Glaz, C. R., Still, B. J., Schriber, J. R., Chao, N. J., Long, G. D., Hoyle, C., Hu, W. W., Horning, S. J., Brown, B. W. et al. (1995). Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood, 85, 3334–3341.
   PubMed Web of Science ®Google Scholar
• Kvalheim, G., Sorensen, O., Fodstad, O., Funderud, S., Kiesel, S., Dorken, B., Nustad, K., Jakobsen, E., Ugelstad, J. and Pihl, A. (1988). Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant., 3, 31–41.
   PubMed Web of Science ®Google Scholar
• Shpall, E. J., Jones, R. B., Bearman, S. I., Franklin, W. A., Archer, P. G., Curiel, T., Bitter, M., Claman, H. N., Stemmer, S. M., Purdy, M., Myers, S. E., Hami, L., Taffs, S., Heimfeld, S., Hallogan, J. and Berenson, R. J. (1994). Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J. Clin. Oncol., 12, 28–36.
   PubMed Web of Science ®Google Scholar
• Berenson, R. J., Bensinger, W. I., Hill, R. S., Andrews, R. G., Garcia-Lopez, J., Kalamasz, D. F., Still, B. J., Spitzer, G., Buckner, C. D., Bernstein, I. D. and Thomas, E. D. (1991). Engraftment after infusion of CD34+marrow cells in patients with breast cancer or neuroblastoma. Blood, 77, 1717–1722.
   PubMed Web of Science ®Google Scholar
• Shpall, E., LeMaistre, C., Holland, K., Ball, E., Jones, R., Saral, R., Jacobs, C., Heimfeld, S., Berenson, R. and Champlin, R. (1997). A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood, 90, 4313–4320.
   PubMed Web of Science ®Google Scholar
• Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Sahebi, F., Lee, M., Wu, C. H., Cao, J., Lee, J. C., Hong, C. H., Lichtenstein, A., Lill, M., Hall, J., Berenson, R. and Berenson, J. (1995). Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood, 86, 390–397.
   PubMed Web of Science ®Google Scholar
• Gorin, N.-C., Lopez, M., Laporte, J.-P., Quittet, P., Lesage, S., Lemoine, F., Berenson, R. J., Isnard, F., Grande, M., Stachowiak, J., Labopin, M., Fouillard, L., Morel, P., Jouet, J.-P., Noel-Walter, M.-P., Detourmignies, L., Aoudjhane, M., Bauters, F., Najman, A. and Douay, L. (1995). Preparation and successful engraftment of purified CD34+bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood, 85, 1647–1654.
   PubMed Web of Science ®Google Scholar
• Watts, M., Sullivan, A., Ings, S., Leverett, D., Peniket, A., Perry, A., Williams, C., Devereux, S., Goldstone, A. and Linch, D. (1997). Evaluation of clinical scale CD34+cell purification: experience of 71 immunoaffinity column procedures. Bone Marrow Transplant, 20, 157–162.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Rowley, S., Appelbaum, F. R., Mills, B., Oldham, F., Chauncey, T. and Buckner, C. D. (1995). CD34 selected allogeneic peripheral blood stem cell (PBPC) transplantation in older patients with advanced hematologic malignancies. Blood, 86, 97a.
   Web of Science ®Google Scholar
• Hagenbeek, A., Schultz, F. W. and Martens, A. C. M. (1994). The role of purging in autologous bone marrow transplantation: theoretical considerations. In: Clinical Bone Marrow Transplantation, Atkinson, K. (Ed.) pp. 164–168. Melbourne, Australia, Cambridge University Press.
   Google Scholar
• Brenner, M. K., Rill, R. D., Moen, R. C., Kranee, R. A., Mirro, J., Anderson, M. F. and Ihle, W. F. (1993). Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet, 341, 85–86.
   PubMed Web of Science ®Google Scholar
• Deisseroth, A. B., Zu, Z., Claxton, D., Hanania, E. G., Fu, S., Ellerson, D., Goldberg, L., Thomas, M., Janicek, K., Anderson, W. F., Hester, J., Körbling, M., Durett, A., Moen, R., Berenson, R., Heimfeld, S., Brenner, M., Hamer, J., Calvert, L., Tibbits, P., Talpaz, M., Kantarjian, H., Champlin, R. and Reading, C. (1994). Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in CML. Blood, 83, 3068–3076.
   PubMed Web of Science ®Google Scholar
• Philip, T., Guglielmi, C., Hagenbeenk, A., Somers, R., Lelie, H. V. D., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J., Harousseau, J., Coiffier, B., Biron, P., Mandelli, G. and Chauvin, G. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med., 333, 1540–1545.
   PubMed Web of Science ®Google Scholar
• Gianni, A. M., Bregni, M., Siena, S., Brambilla, C., DiNicola, M., Lombardi, F., Gandola, L., Tarella, C., Pileri, A., Ravagnani, F., Valagussa, P. and Bonadonna, G. (1997). High-dose chemotherapy and autologous bone marrow transplantation compared with MACOPB in aggressive B-cell lymphoma. N. Engl. J. Med., 336, 1290–1297.
   PubMed Web of Science ®Google Scholar
• Gribben, J. G., Neuberg, D., Freedman, A. S., Gimmi, C. D., Pesek, K. W., Barber, M., Saporito, L., Woo, S. D., Coral, F., Spector, N., Rabinowe, S. N., Grossbard, M. L., Ritz, J., Nadler, L. M. (1993). Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood, 81, 3449–3457.
   PubMed Web of Science ®Google Scholar
• Williams, C. D., Goldstone, A. H., Pearce, R. M., Philip, T., Harmann, O., Colombat, P., Santini, G., Foulard, L. and Gorin, N. C. (1996). Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J. Clin. Oncol., 14, 2454–2464.
   PubMed Web of Science ®Google Scholar
• Biernaux, C., Loos, M., Sels, A., Huez, G. and Stryckmans, P. (1995). Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood, 86, 3118–3122.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Hernandez, A. M., Shibata, D. and Cortopassi, G. A. (1994). BCL2 translocation frequency rises with age in humans. Proc. Natl. Acad. Sci., 91, 8910–8914.
   PubMed Web of Science ®Google Scholar
• Haas, R., Moos, M., Karcher, A., Mohle, R., Witt, B., Goldschmidt, H., Fruhauf, S., Flentje, M., Wannenmacher, M. and Hunstein, W. (1994). Sequential high-dose therapy with peripheral blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J. Clin. Oncol., 12, 1685–1692.
   PubMed Web of Science ®Google Scholar
• Finke, J., Slanina, J., Lange, W., Dolken, G. (1993). Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J. Clin. Oncol., 11, 1668–1673.
   PubMed Web of Science ®Google Scholar
• Gribben, J. G., Neuberg, D., Barber, M., Moore, J., Pesek, K. W., Freedman, A. S. and Nadler, L. M. (1994). Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse that detection in bone marrow. Blood, 83, 3800–3807.
   PubMed Web of Science ®Google Scholar
• Johnson, P. W. M., Price, C. G. A., Smith, T., Cotter, F. E., Meerbaux, J., Rohatiner, A. Z. S., Young, B. D. and Lister, T. A. (1994). Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J. Clin. Oncol., 12, 798–805.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Jagannath, S., Vesole, D. and Tricot, G. (1995). Autologous and allogeneic transplants for multiple myeloma. Sem. Hematol., 32, 31–44.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Rowley, S. D., Demirer, T., Lilleby, K., Schiffman, K., Clift, R. A., Appelbaum, F. R., Fefer, A., Barnett, T., Storb, R., Chauncey, T., Maziarz, R. T., Klarnet, J., McSweeney, P., Holmberg, L., Maloney, D. G., Weaver, C. and Buckner, C. D. (1996). High-dose therapy followed by autologous hematopoietic stem cell infusion for patients with multiple myeloma. J. Clin. Oncol., 14, 1447–1456.
   PubMed Web of Science ®Google Scholar
• Attal, M., Harousseau, J.-L., Stoppa, J. J., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. and Bataille, R. (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med., 335, 91–97.
   PubMed Web of Science ®Google Scholar
• Anderson, K. C., Andersen, J., Soiffer, R., Freedman, A. S., Rabinowe, S. N., Robertson, M. J., Spector, N., Blake, K., Murray, C., Freeman, A., Coral, F., Marcus, K. C, Mauch, P., Nadler, L. M. and Ritz, J. (1993). Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood, 82, 2568–2576.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Demirer, T., Buckner, C. D., Appelbaum, F. R., Storb, R., Lilleby, K., Weiden, P., Bluming, A. Z. and Fefer, A. (1996). Syngeneic marrow transplantation in patients with multiple meyloma. Bone Marrow Transplant, 18, 527–531.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Buckner, C. D., Anasetti, C., Clift, R., Storb, R., Barnett, T., Chauncey, T., Shulman, H. and Appelbaum, F. R. (1996). Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood, 88, 2787–2793.
   PubMed Web of Science ®Google Scholar
• Diel, I. J., Kaufmann, M., Goerner, R., Costa, S. D., Kaul, S. and Bastert, G. (1992). Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J. Clin. Oncol., 10, 1534–1539.
   PubMed Web of Science ®Google Scholar
• Fields, K. K., Elfenbein, G. J., Trudeau, W. L., Perkins, J. B., Janssen, W. E. and Moscinski, L. C. (1996). Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J. Clin. Oncol., 14, 1868–1876.
   PubMed Web of Science ®Google Scholar
• Ross, A. A., Cooper, B. W., Lazarus, H. M., Mackay, W., Moss, T. J., Ciobanu, N., Tallman, M. S., Kennedy, M. J., Davidson, N. E., Swet, D., Winter, C., Akard, L., Jansen, J., Copellan, E., Meagher, R. C., Herzig, R. H., Klumpp, T. R., Kahn, D. G. and Warner, N. E. (1993). Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood, 82, 2605–2610.
   PubMed Web of Science ®Google Scholar
• Weaver, C., Hazelton, B., Ross, A. and Schwartzberg, L. (1995, abstr). The incidence of tumor cell contamination in peripheral blood progenitor cell (PBPC) collections in patients with breast cancer. J. Hematother. ISHAGE 2nd International Meeting: 4A43.
   Google Scholar
• Shpall, E. J., Jones, R. B., Bast, R. C. Jr., Rosner, G. L., Vandermark, R., Ross, M., Affronti, M. L., Johnston, C., Eggleston, S., Tepperburg, M., Coniglio, D. and Peters, W. P. (1991). 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J. Clin. Oncol., 9, 85–93.
   PubMed Web of Science ®Google Scholar
• Shpall, E., Bast, R. J., Jones, W., Jones, R., Anderson, I., Johnston, C., Eggleston, S., Tepperberg, M., Edwards, S. and Peters, W. (1991). Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant, 7, 145–151.
   PubMed Web of Science ®Google Scholar
• Verma, U. N., Areman, E., Dickerson, S. A., Kotula, P. L., Sacher, R. and Mazumder, A. (1995). Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant, 15, 199–206.
   PubMed Web of Science ®Google Scholar
• Verma, U., Charak, B., Rajagopal, C. and Mazumder, A. (1995). Interleukin-2 in bone marrow transplantation. In: Technical and biological components of marrow transplantation, Buckner, C. D. and Clift, R. A. (Eds.) pp. 315–336. Boston, MA., Kluwer Academic Publishers.
   Google Scholar
• Benyunes, M. C., Massumoto, C., Higuchi, C. M., Buckner, C. D., Thompson, J. A., Peterson, F. B. and Fefer, A. (1993). Interleukin-2+/- lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant, 12, 159–163.
   PubMed Web of Science ®Google Scholar
• Meloni, G., Foa, R., Vignetti, M., Guarini, A., Fenu, S., Tosti, S., Gillio Tos, A. and Mandelli, F. (1994). Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood, 84, 2158–2163.
   PubMed Web of Science ®Google Scholar
• Nagler, A., Ackerstein, A., Barak, V. and Slavin, S. (1994). Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-a2a. J. Hematopath, 3, 75.
   Google Scholar
• Verfaillie, C., Miller, W., Kay, N. and McGlave, P. (1989). Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Blood, 74, 793.
   PubMed Web of Science ®Google Scholar
• Miller, J. S., Verfaillie, C. M. and McGlave, P. M. (1990). Adherent lymphokine activated killer (A-LAK) cells preferentially suppress chronic myelogenous leukemia (CML) primitive progenitors. Am. Soc. Hematol., 76, 301a, (abstr).
   Google Scholar
• Cervantes, F., McGlave, P. and Miler, J. S. (1994). Autologous activated natural killer cells (ANK) suppress CML progenitors but spare normal hematopoiesis in long term bone marrow culture (LTC). Am. Soc. Hematol., 84, 150a, (abstr).
   Google Scholar
• Reittie, J. E., Gottlieb, D., Heslop, H. E. et al. (1989). Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood, 73, 1351.
   PubMed Web of Science ®Google Scholar
• Miller, J. S., Tessmer-Tuck, J., Blake, N., Lund, J., Scott, A., Blazar, B. R. and Orchard, P. J. (1997). Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer. Exp. Hematol, 25, 1140–1148.
   PubMed Web of Science ®Google Scholar
• Meropol, N. J., Porter, M., Blumenson, L. E., Lindemann, M. J., Perez, R. P., Vaickus, L., Loewen, G. M., Creaven, P. J., Wilkes, K. A., Giedlin, M. A. and Caligiuri, M. A. (1996). Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo significant toxicity. Clin. Cancer Res., 2, 669–677.
   PubMed Web of Science ®Google Scholar
• Buckner, C. D., Appelbaum, F. R., Clift, R. A., Doney, K., Sanders, J., Hill, R. and Thomas, E. D. (1987). Autotransplants in leukemia: Do they work, how can we tell? In: Progress in Marrow Transplantation, UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 53, Gale, R. P. and Champlin, R. (Eds.), 711–721. New York. Alan R. Liss, Inc.
   Google Scholar
• Weaver, C. H., Moss, T., Schwartzberg, L. S., Zhen, B., West, J., Rhinehart, S., Campos, L., Beeker, T., Lautersztain, L. and Buckner, C. D. (1998). High-dose chemotherapy in patients with breast cancer: impact of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant, 21, 1117–1124.
   PubMed Web of Science ®Google Scholar
• Bensinger, W., Appelbaum, F., Rowley, S., Storb, R., Sanders, J., Lilleby, K., Gooley, T., Demirer, T., Schiffman, K., Weaver, C., Clift, R., Chauncey, T., Klarnet, J., Montgomery, P., Petersdorf, S., Weiden, P., Witherspoon, R. and Buckner, C. D. (1995). Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J. Clin. Oncol., 13, 2547–2555.
   PubMed Web of Science ®Google Scholar
• Bensinger, W. I., Demirer, T., Rowley, S. and Buckner, C. D. (1995). Factors predictive of rapid engraftment after peripheral blood stem cell infusions. Bone Marrow Transplant, 15, S83–S85.
   Google Scholar
• Weaver, C. H., Hazelton, B., Birch, R., Palmer, P., Allen, C., Schwartzberg, L. and West, W. (1995). An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood, 86, 3961–3969.
   PubMed Web of Science ®Google Scholar
• Powles, R., Raje, N., Cunningham, D., Malpas, J., Milan, S., Horton, C., Mehta, J., Singhal, S., Viner, C. and Treleaven, J. (1995). Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells, 13 Suppl 2, 114–117.
   PubMed Web of Science ®Google Scholar